Cargando…

Drug-induced corneal deposits: an up-to-date review

This review assesses different clinical aspects of the various known drug-induced corneal deposits, based on the corneal layer involved (epithelium, stroma and/or endothelium), and based on the drug class. The most well-known condition caused by drug deposits is vortex keratopathy, or corneal vertic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahyoun, Jean-Yves, Sabeti, Saama, Robert, Marie-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961126/
https://www.ncbi.nlm.nih.gov/pubmed/35415268
http://dx.doi.org/10.1136/bmjophth-2021-000943
_version_ 1784677529774194688
author Sahyoun, Jean-Yves
Sabeti, Saama
Robert, Marie-Claude
author_facet Sahyoun, Jean-Yves
Sabeti, Saama
Robert, Marie-Claude
author_sort Sahyoun, Jean-Yves
collection PubMed
description This review assesses different clinical aspects of the various known drug-induced corneal deposits, based on the corneal layer involved (epithelium, stroma and/or endothelium), and based on the drug class. The most well-known condition caused by drug deposits is vortex keratopathy, or corneal verticillata, which is a whorl-like opacity in the corneal epithelium. Vortex keratopathy is commonly caused by certain cationic amphiphilic drugs such as amiodarone, antimalarials, suramin, tamoxifen, chlorpromazine and non-steroidal anti-inflammatory drugs. These deposits usually occur once a certain dose of the drug is reached. Most cases present with mild to moderate symptoms with minimal visual impairment. Most of these deposits resolve automatically, after months to years of drug cessation. Notably, other drug classes can cause deposits in all three layers of the cornea. Chlorpromazine, gold, rifabutin, indomethacin and tyrosine kinase inhibitors can cause stromal deposits, with reduced visual acuity when the anterior stroma is involved. Chlorpromazine and rifabutin can also cause deposits in the endothelial layer of the cornea. Regardless of the type of corneal deposit, local therapies such as topical lubricants or corticosteroids may help improve symptoms. Drug cessation or modification can also be helpful but should be weighed against the systemic risks of the underlying disease.
format Online
Article
Text
id pubmed-8961126
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89611262022-04-11 Drug-induced corneal deposits: an up-to-date review Sahyoun, Jean-Yves Sabeti, Saama Robert, Marie-Claude BMJ Open Ophthalmol Review This review assesses different clinical aspects of the various known drug-induced corneal deposits, based on the corneal layer involved (epithelium, stroma and/or endothelium), and based on the drug class. The most well-known condition caused by drug deposits is vortex keratopathy, or corneal verticillata, which is a whorl-like opacity in the corneal epithelium. Vortex keratopathy is commonly caused by certain cationic amphiphilic drugs such as amiodarone, antimalarials, suramin, tamoxifen, chlorpromazine and non-steroidal anti-inflammatory drugs. These deposits usually occur once a certain dose of the drug is reached. Most cases present with mild to moderate symptoms with minimal visual impairment. Most of these deposits resolve automatically, after months to years of drug cessation. Notably, other drug classes can cause deposits in all three layers of the cornea. Chlorpromazine, gold, rifabutin, indomethacin and tyrosine kinase inhibitors can cause stromal deposits, with reduced visual acuity when the anterior stroma is involved. Chlorpromazine and rifabutin can also cause deposits in the endothelial layer of the cornea. Regardless of the type of corneal deposit, local therapies such as topical lubricants or corticosteroids may help improve symptoms. Drug cessation or modification can also be helpful but should be weighed against the systemic risks of the underlying disease. BMJ Publishing Group 2022-03-25 /pmc/articles/PMC8961126/ /pubmed/35415268 http://dx.doi.org/10.1136/bmjophth-2021-000943 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Sahyoun, Jean-Yves
Sabeti, Saama
Robert, Marie-Claude
Drug-induced corneal deposits: an up-to-date review
title Drug-induced corneal deposits: an up-to-date review
title_full Drug-induced corneal deposits: an up-to-date review
title_fullStr Drug-induced corneal deposits: an up-to-date review
title_full_unstemmed Drug-induced corneal deposits: an up-to-date review
title_short Drug-induced corneal deposits: an up-to-date review
title_sort drug-induced corneal deposits: an up-to-date review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961126/
https://www.ncbi.nlm.nih.gov/pubmed/35415268
http://dx.doi.org/10.1136/bmjophth-2021-000943
work_keys_str_mv AT sahyounjeanyves druginducedcornealdepositsanuptodatereview
AT sabetisaama druginducedcornealdepositsanuptodatereview
AT robertmarieclaude druginducedcornealdepositsanuptodatereview